Blog Archives

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

August 1, 2016
BÜHLMANN fCAL® ELISA Citation Seenan, JP,Thomson,Rankin K,Smith K, Gaya DR.Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology.  2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467. “we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.” Learn More
Continue Reading →

Fecal Calprotectin in Inflammatory Bowel Disease

August 1, 2016
BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood.  Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi:  10.2147/CEG.S51902 “The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features
Continue Reading →

Diagnostic Accuracy and Clinical Application of Faecal Calprotectin in Adult Patients Presenting with Gastrointestinal Symptoms in Primary Care

August 1, 2016
BÜHLMANN fCAL® ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771. “This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA] testing in primary care…..to be
Continue Reading →

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.

August 1, 2016
Quantum Blue® Calprotectin Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. “We found FC to be a very accurate
Continue Reading →